Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SAB Biotherapeutics, Inc. (SABS)

SAB Bio: Breakthrough T1D grant funds PRISE-hATG study of SAB-142 in Stage 3 T1D

Neutral Impact 2 of 5 product/contract Written later

SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., University of Florida, to support the PRISE-hATG clinical study of SAB-142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis. SAB BIO will co-fund the study, which extends its clinical evaluation of SAB-142 beyond the Phase 2b SAFEGUARD trial; the filing gives no financial amount for the grant or the company's share of costs.

Key points

  • Breakthrough T1D awarded the grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida, dated July 7, 2026.
  • PRISE-hATG evaluates SAB-142 in patients 100 days to 2 years from a Stage 3 T1D diagnosis.
  • SAB BIO will co-fund the study alongside the complementary Phase 2b SAFEGUARD trial.
  • The filing does not disclose grant or co-funding amounts.

The filing

CompanySAB Biotherapeutics, Inc. (SABS)
Form8-K, current report
Filed with the SECJul 7, 2026, 8:15 AM ET
Accession number0001193125-26-296936

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.